Abcam (ABCZF) Change In Receivables : $-41.1 Mil (TTM As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Abcam Change In Receivables?

Abcam's change in receivables for the quarter that ended in Jun. 2023 was $-15.8 Mil. It means Abcam's Accounts Receivable increased by $15.8 Mil from Dec. 2022 to Jun. 2023 .

Abcam's change in receivables for the fiscal year that ended in Dec. 2022 was $-40.6 Mil. It means Abcam's Accounts Receivable increased by $40.6 Mil from Jun. 2020 to Dec. 2022 .

Abcam's Accounts Receivable for the quarter that ended in Jun. 2023 was $116.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Abcam's Days Sales Outstanding for the six months ended in Jun. 2023 was 82.90.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Abcam's liquidation value for the six months ended in Jun. 2023 was $-159.8 Mil.

Abcam Change In Receivables Historical Data

The historical data trend for Abcam's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Change In Receivables Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

Change In Receivables

Get a 7-Day Free Trial

-1.02

-7.58

-7.73

3.38

-40.56

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															-10.35	-	-15.39	-25.34	-15.78

Abcam Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-41.1 Mil.

Abcam (OTCPK:ABCZF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Abcam's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	116.54	/	256.566	*	91
=	82.90

2. In Ben Graham's calculation of liquidation value, Abcam's accounts receivable are only considered to be worth 75% of book value:

Abcam's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	99.747	-	388.763	+	0.75 * 116.54	+	0.5 * 83.712
=	-159.8

Abcam Change In Receivables Related Terms

Thank you for viewing the detailed overview of Abcam's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam (ABCZF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.